The ongoing EVOKE-02 trial (NCT05186974) is assessing SG with pembrolizumab ± platinum chemotherapy in treatment-naïve metastatic NSCLC with PD-L1 ≥ 50% and no actionable alterations. Here, CD274 is linked to non-small cell lung carcinoma.